For US Healthcare Professionals

Understanding Psoriasis and Psoriatic Arthritis: Patient FAQs

FAQs about PsoriaSiblings

Disease connection and pathophysiology

PsO, PsA, and IBD are genetically and immunologically linked systemic inflammatory conditions that share common pathogenic cytokines and barrier dysfunction along the skin-gut-joint axis.1-4 This bidirectional association is demonstrated by shared genetic susceptibility loci and elevated risk of developing secondary comorbidities across these organ systems.1,4

Cutaneous psoriasis is the outer manifestation of a wider systemic inflammatory state, driven by circulating inflammatory mediators that propagate multiorgan comorbidities including subclinical enthesitis, metabolic syndrome, and cardiovascular disease.5-7 Consequently, treating the disease solely as a localized dermatological condition overlooks the progressive systemic damage occurring throughout the vasculature and musculoskeletal systems.8

Pathophysiologically, these overlapping immune pathways are driven by a shared dysregulation of the innate and adaptive immune systems, primarily mediated by the interleukin (IL)-23/IL-12 producing tumor necrosis factor-alpha (TNF-α) and downstream IL-17.2,9,10 This inflammatory cascade disrupts epithelial and synovial barriers, driving localized tissue damage and hyperproliferation in the skin, synovium, and intestinal mucosa.2,9,10

IL-23 acts as the upstream regulator by binding to its receptor on Th17 cells and innate lymphoid cells, driving their survival, expansion, and production of pathogenic cytokines like IL-17 and IL-22.2 Selective inhibition of the p19 subunit of IL-23 effectively modulates this chronic inflammatory response at its source, providing a highly targeted therapeutic approach.2

Epidemiology and risk

Approximately 30% of patients diagnosed with psoriasis may subsequently develop psoriatic arthritis.7,8,11 In ~75%-80% of these cases, the dermatological lesions precede joint symptoms by an average of 7 to 12 years, which may help provide a vital window for early screening and intervention.6,7

Yes, up to 15% of patients present with joint symptoms prior to the onset of cutaneous lesions, and a small subset may present with "psoriatic arthritis sine psoriasis," characterized by active arthritis in the complete absence of historical skin lesions.7,12,13 In these cases, a confirmed family history of psoriasis serves as a critical diagnostic surrogate under established classification criteria.13

Large cohort studies indicate that up to 2.4% of patients with psoriasis are diagnosed with co-existing IBD, representing a 1.5- to 2.5-fold increased relative risk compared to the general population.14,15 This correlation is highly pronounced in patients with severe psoriasis, who exhibit a significantly higher hazard ratio for developing Crohn's disease and ulcerative colitis.14,15

Patients with severe cutaneous involvement (eg, high Psoriasis Area and Severity Index [PASI] scores), nail dystrophy, scalp lesions, and intergluteal or perianal psoriasis carry the highest risk of progression to psoriatic arthritis.6 The risk of progressing to inflammatory bowel disease is similarly elevated in patients with severe skin disease, concomitant spondyloarthropathies, and specific metabolic comorbidities like type 2 diabetes.6,15

Dermatologists should screen for a family history of PsO and PsA, as approximately 30% of patients with PsO may develop PsA.11,16 High-risk genetic markers include the HLA-Cw*0602 allele for psoriasis susceptibility, HLA-B27/B38/B39 for psoriatic arthritis, and shared susceptibility loci within the IL-23 receptor gene (IL-23R) across all 3 conditions.14,16,17

Early identification and screening

Early markers of psoriatic arthritis transition include persistent morning joint stiffness lasting over 30 minutes, unspecific joint pain (arthralgia), dactylitis ("sausage digits"), and inflammatory enthesitis such as Achilles tendinitis.6,7

Severe plaque psoriasis, scalp psoriasis, intergluteal/perianal involvement, and especially psoriatic nail dystrophy are strongly correlated with an increased risk of PsA.6 Nail matrix and nail bed inflammation directly reflect microanatomical disease of the distal interphalangeal (DIP) joint due to the close anatomical relationship between the nail unit and the DIP enthesis.6,18

Dermatologists can implement validated, self-administered screening questionnaires such as the Psoriasis Epidemiology Screening Tool (PEST), the Early Arthritis for Psoriatic Patients (EARP), or the Psoriatic Arthritis Uncluttered Screening Evaluation (PURE-4).19,20 These screening questionnaires are highly efficient in outpatient settings for quickly identifying patients requiring formal rheumatological consultation.20

Psoriatic arthritis is formally classified using the Classification Criteria for Psoriatic Arthritis (CASPAR), which require the presence of active inflammatory musculoskeletal disease plus at least 3 points from categories including personal/family history of psoriasis, nail dystrophy, negative rheumatoid factor, dactylitis, and radiological juxta-articular bone formation.21 This validated diagnostic framework offers high specificity and sensitivity, even in atypical presentations.21

Frequent screening is essential given that musculoskeletal symptoms can develop at any phase of the disease continuum, even in patients under active systemic therapy.11,20,22

Clinical "red flags" prompting suspicion of coexisting IBD include chronic abdominal pain, persistent diarrhea (especially nocturnal), rectal bleeding, unexplained weight loss, and oral aphthous stomatitis.23,24 Extraintestinal skin findings such as erythema nodosum or pyoderma gangrenosum should also trigger immediate gastrointestinal evaluation.24

Practice implications

A prompt referral to rheumatology is indicated if a patient presents with any positive screening tool score (eg, PEST ≥3 or PURE-4 ≥1) or symptoms of inflammatory joint pain, dactylitis, or enthesitis.19,20 Gastroenterology referral should be initiated immediately upon the presentation of persistent red-flag GI symptoms, particularly chronic diarrhea, rectal bleeding, or unexplained weight loss.23

A coordinated care model involving dermatologists, rheumatologists, and gastroenterologists ensures a holistic, nonsiloed therapeutic approach that optimizes the choice of systemic or biologic therapy to benefit multiple organ domains simultaneously.9,20

A diagnostic delay of 6 months from the onset of musculoskeletal symptoms may be associated with progressive, irreversible joint erosions, structural damage, and worse long-term functional and radiographic outcomes.6,25

Help stop PsoriaSiblings from making themselves at home under your patient's skin

Explore a treatment option

References

  1. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-848. doi:10.1111/bjd.18245
  2. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
  3. Gracey E, Dumas E, Yerushalmi M, Qaiyum Z, Inman RD, Elewaut D. The ties that bind: skin, gut and spondyloarthritis. Curr Opin Rheumatol. 2019;31(1):62-69. doi:10.1097/BOR.0000000000000569
  4. Sun Y, Li Y, Zhang J. The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases. Sci Rep. 2022;12(1):20526. doi:10.1038/s41598-022-24872-5
  5. Rech J, Sticherling M, Stoessel D, Biermann MHC, Häberle BM, Reinhardt M. Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. 2020;4(2):rkaa033. doi:10.1093/rap/rkaa033
  6. Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020;31(7):662-679. doi:10.1080/09546634.2019.1605142
  7. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423-441. doi:10.1007/s40265-014-0191-y
  8. Felix PAO, Sampaio AL, Silva BL, Viana ALP. Early intervention in psoriasis: where do we go from here? Front Med (Lausanne). 2022;9:1027347. doi:10.3389/fmed.2022.1027347
  9. Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing psoriatic arthritis with inflammatory bowel disease and/or uveitis. Front Med (Lausanne). 2021;8:737256. doi:10.3389/fmed.2021.737256
  10. Spanopoulou C, Katsimbri P. Psoriatic arthritis: developments in 2025. Mediterr J Rheumatol. 2026;37(suppl 1):12-20. doi:10.31138/mjr.200925.per
  11. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729-735. doi:10.1016/j.jaad.2013.07.023
  12. Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410-1416. doi:10.3899/jrheum.201199
  13. Olivieri I, Padula A, D'Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009;36(Suppl 83):28-29. doi:10.3899/jrheum.090218
  14. Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckland). 2016;6:73-92. doi:10.2147/PTT.S85194
  15. Grossi G. Psoriasis severity tied to increased risk of inflammatory bowel disease. AJMC. February 26, 2024. Accessed August 6, 2026. https://www.ajmc.com/view/psoriasis-severity-tied-to-incrased-risk-of-inflammatory-bowel-disease
  16. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14(6):363-371. doi:10.1038/s41584-018-0006-8
  17. Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. doi:10.3389/fimmu.2024.1331217
  18. Elliott A, Pendleton A, Wright G, Rooney M. The relationship between the nail and systemic enthesitis in psoriatic arthritis. Rheumatol Adv Pract. 2021;5(3):1-8. https://doi.org/10.1093/rap/rkab088
  19. Kimak A, Robak E, Makowska J, Woźniacka A. Psoriatic arthritis: development, detection and prevention: a scoping review. J Clin Med. 2023;12:3850. https://doi.org/10.3390/jcm12113850
  20. Gottlieb AB, Merola JF. Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol. 2021;84(1):92-101. doi:10.1016/j.jaad.2020.05.089
  21. Hassan R, Faruqui H, Alquraa R, et al. Classification criteria and clinical practice guidelines for rheumatic diseases. In: Almoallim H, Cheikh M, eds. Skills in Rheumatology. 2021. https://doi.org/10.1007/978-981-15-8323-0_25
  22. Karreman MC, Weel AEAM, van der Ven M, et al. Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology (Oxford). 2017;56:597-602. doi:10.1093/rheumatology/kew410
  23. Sanz Sanz J, Juanola Roura X, Seoane-Mato D, Montoro M, Gomollón F; Grupo de Trabajo del proyecto PIIASER. Screening of inflammatory bowel disease and spondyloarthritis for referring patients between rheumatology and gastroenterology. Criterios de cribado de enfermedad inflamatoria intestinal y espondiloartritis para derivación de pacientes entre reumatología y gastroenterología. Reumatol Clin. 2018;14(2):68-74. doi:10.1016/j.gastrohep.2017.03.012
  24. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(4):235-241.
  25. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050. doi.org/10.1136/annrheumdis-2013-204858